SHEN Heng, WEI Hui, TAN Jia-qi. 5-Year Follow-Up Results of CPX-351 Versus 7+3 Chemotherapy in Older Adults With Newly Diagnosed High-Risk or Secondary Acute Myeloid Leukaemia[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 84-86. DOI: 10.12019/j.issn.1671-5144.2022.02.003
|
Citation:
|
SHEN Heng, WEI Hui, TAN Jia-qi. 5-Year Follow-Up Results of CPX-351 Versus 7+3 Chemotherapy in Older Adults With Newly Diagnosed High-Risk or Secondary Acute Myeloid Leukaemia[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 84-86. DOI: 10.12019/j.issn.1671-5144.2022.02.003
|
SHEN Heng, WEI Hui, TAN Jia-qi. 5-Year Follow-Up Results of CPX-351 Versus 7+3 Chemotherapy in Older Adults With Newly Diagnosed High-Risk or Secondary Acute Myeloid Leukaemia[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 84-86. DOI: 10.12019/j.issn.1671-5144.2022.02.003
|
Citation:
|
SHEN Heng, WEI Hui, TAN Jia-qi. 5-Year Follow-Up Results of CPX-351 Versus 7+3 Chemotherapy in Older Adults With Newly Diagnosed High-Risk or Secondary Acute Myeloid Leukaemia[J]. Journal of Evidence-Based Medicine, 2022, 22(2): 84-86. DOI: 10.12019/j.issn.1671-5144.2022.02.003
|
DownLoad: